The Lung-Drug Maker That Just Settled Its Way Out of a Patent Trap

30‑Second Take

Here's the setup. Liquidia (NASDAQ: LQDA) sells Yutrepia, a dry-powder inhaled form of treprostinil for pulmonary arterial hypertension (PAH). It goes head-to-head with United Therapeutics' Tyvaso DPI, and the launch is working: preliminary Q3 Yutrepia net sales came in at $222.7 million.

On September 30, a Delaware court ruled that Yutrepia infringed a United Therapeutics patent, and the stock lost more than half its value that day.

Then, after the close on October 13, the two companies announced a global settlement of all pending litigation. Liquidia keeps selling Yutrepia in PAH. The stock jumped about 27% the next session as BTIG upgraded it to Buy with a $70 target.

What matters to you now: the legal overhang that crushed the stock is gone, but peace has a price. Liquidia pays United Therapeutics a $175 million net payment plus $145.4 million in two installments due by January 31 and April 30, 2027, and it will ask the FDA to remove the PH-ILD indication from its label. That trade-off is what you're buying into.

Trade Setup

Timeframe: Swing to position (2 to 6 months)

Edge type: Legal overhang removed plus a fresh upgrade, with heavy call buying on settlement day

The thesis is simple. The worst legal outcome is off the table, the PAH launch keeps its runway, and the stock still sits at roughly half its pre-ruling price. BTIG called the deal better than its best-case scenario.

Needham kept its Buy but cut its target to $58 from $72 on the settlement costs. The risk is that PAH alone can't carry the growth story without PH-ILD. That's your watch item.

Snapshot Table

Chart

1-Month Trading Summary

It's been a round trip. LQDA traded around $70 through late September, then lost about 57% on September 30 after the patent ruling and spent the next two weeks in the high $20s.

The settlement sparked a roughly 27% jump on October 14 on more than 20 million shares, about 7 times its normal volume, and the stock held the gain the next day. It's still down about half over the past month, so you're buying a stock that has won back only a slice of the ruling's damage.

Bull Case 

Why It Works

Yutrepia is the whole story, and the launch is real. Treprostinil is a standard therapy in PAH, a market United Therapeutics has dominated for years with Tyvaso. Liquidia's dry-powder version launched in June 2025, and $222.7 million in preliminary Q3 sales tells you doctors are writing it.

The settlement is what changes the math. Before October 13, Yutrepia's future hung on a court fight Liquidia had just lost. Now every pending case is resolved, Liquidia keeps selling in PAH, and it ended September with $396.1 million in cash to cover the payments. You can judge the launch on its own merits again.

The Catalysts

The settlement-day signal was loud. Traders bought more than 30,000 LQDA calls on October 14, far above the usual pace, the same morning BTIG upgraded the stock and called the deal better than its best case. When options flow and an upgrade line up on a binary event like this, the market is telling you the lawsuit was the main thing holding the stock down.

Next up: final Q3 results and management's first full commentary on life after the settlement (Finnhub lists November 10; the company hasn't confirmed a date), plus PAH prescription trends and any update on the label change. Any one of those can extend the move.

What The Numbers Say

The numbers back the story. $222.7 million of quarterly Yutrepia sales annualizes to roughly $890 million, against a market cap around $3 billion. Liquidia's PRINT particle platform also gives it a pipeline beyond Yutrepia, including the L606 program it plans to keep advancing.

BTIG's $70 target would roughly double the stock and sits right about where shares traded before the ruling. Needham's more cautious $58 still implies big upside. Even if the truth lands between the two, you have a defined thesis with real numbers behind it.

Bear Case 

What Could Break It

Specialty drug launches can stall. Prescriptions don't always translate into booked revenue because of payer dynamics, specialty pharmacy stocking, and physician inertia. And with PH-ILD coming off the label, Yutrepia gives up a growth market it had been counting on. If PAH demand flattens, the stock can give back the settlement pop fast, so size your position for the Q3 print.

United Therapeutics isn't rolling over either. It has the sales force, the physician relationships, and the balance sheet to defend Tyvaso aggressively, and now it collects settlement cash from Liquidia too. Expect price pressure, co-pay programs, and real-world data pushes.

The Valuation Risk

The 52-week range shows how volatile this stock can be, from the low $20s to the low $90s. The settlement also costs real money: $175 million net plus $145.4 million due in 2027. That cash isn't going into the launch, so watch how management guides spending.

How To Size It

Size the position so a 30% drawdown doesn't make you panic sell. Set a stop in the $26 to $28 zone, near the post-ruling lows. If the Q3 call shows PAH demand holding up without PH-ILD, add on strength.

Quick Checklist 

✅ Thesis still valid after the settlement terms
✅ Volume confirms the move back above $30
✅ Catalyst dates double-checked (settlement Oct 13, BTIG upgrade Oct 14, Q3 report expected around Nov 10)

Deep‑Dive Links

• Latest earnings report

• Analyst ratings and price targets

• Short interest data

• Company profile and investor relations

That’s all for today’s Everyday Alpha. We’ll have a new pick for you every morning before the market opens, so stay tuned!

Best Regards,
—Noah Zelvis
Everyday Alpha